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Abstract The abnormal activation of telomerase, codified by
the telomerase reverse transcriptase (TERT) gene, is related to
one of cancer hallmarks. Hotspot somatic mutations in the
promoter region of TERT, specifically the c.-124:C>T and
c.-146:C>T, were recently identified in a range of human can-
cers and have been associated with a more aggressive behav-
ior. Testicular germ cell tumors frequently exhibit a good
prognosis; however, the development of refractory disease is
still a clinical challenge. In this study, we aim to evaluate for
the first time the presence of the hotspot telomerase reverse
transcriptase gene promoter mutations in testicular germ cell
tumors. A series of 150 testicular germ cell tumor cases and
four germ cell tumor cell lines were evaluated by PCR follow-
ed by direct Sanger sequencing and correlated with patient’s
clinical pathological features. Additionally, we genotyped the
telomerase reverse transcriptase gene promoter single nucleo-
tide polymorphism rs2853669 (T>C) located at −245 position.
We observed the presence of the TERT promoter mutation in
four patients, one exhibited the c.-124:C>T and three the c.-
146:C>T. No association between TERT mutation status and
clinicopathological features could be identified. The analysis
of the rs2853669 showed that variant C was present in 22.8 %
of the cases. In conclusion, we showed for the first time that
TERT promoter mutations occur in a small subset (~3 %) of
testicular germ cell tumors.
Keywords Testicular neoplasms . Neoplasms, germ cell, and
embryonal . TERT protein . Mutation . Polymorphism, single
nucleotide
Introduction
Telomere maintenance and regulation are fundamental for
normal cell homeostasis, and telomerase activity is central in
this process [1]. One of the key human cancer hallmarks is the
abnormal upregulation of telomerase, that is codified by the
telomerase reverse transcriptase (TERT) gene [1]. Recent
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studies identified the presence of hotspot somatic mutations in
the promoter region of TERT gene, specifically the −124:C>T
and −146:C>Tmutations, in a range of human cancers such as
bladder, gliomas, thyroid and melanoma [2–5]. These muta-
tions have been shown to create a new binding motif sites for
ETS transcription factors, which induces upregulation of
TERT levels [2, 5, 6]. Recently, the less frequent variant C
of the single nucleotide polymorphism (SNP) rs2853669 lo-
cated −245 bp upstream from the ATG start site of the TERT
promoter region has been shown to decrease TERT expression
levels in both −124:C>T and −146:C>T mutant cases, appar-
ently introducing a protective effect [7]. In accordance, this
rs2853669 SNP modifies the clinical outcomes in bladder
cancer and renal cell carcinoma [8, 9].
Testicular germ cell tumor (TGCT) is the most frequent
malignant neoplasm in young man, representing 95 % of the
testicular cancers [10]. Commonly, TGCTs are classified in
two distinct groups, the seminomas (SE) and the non-
seminomas (non-SE), with a slight predominance of the last
group and frequently appearing as a mixed tumor containing
both histologies. The mainstay TGCT treatment over the last
decades has been platinum-based chemotherapy associated
with surgery, leading to high response rates and also in some
cases to a curable disease [11]. Nevertheless, the development
of refractory disease is still a challenge in around 15 % of the
cases, and even within this group, there is a large range of risk
[12, 13]. Currently, the risk stratification of the patients is
based only on clinical parameters as the spreading pattern
and serum levels of human chorionic gonadotropin (hCG),
alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH).
It is well known that telomerase activity is present in nor-
mal testicular tissue and in TGCT, and its activity level has
been inversely related to the differentiation state of clinical
germ cell tumors [14]. Recently, a GWAS study reported an
association of TGCT and genetic variants on the TERT locus,
on chromosome 5, suggesting the role of TERT gene on
TGCT tumorigenesis [15]. However, the molecular mecha-
nism associated with telomerase activation in different types
of germ cell tumors are complex and remain unclear. Herein,
we evaluated the presence and clinicopathological impact of
somatic mutations and rs2853669 polymorphism in the pro-
moter region of TERT gene in a population of Brazilian and
Portuguese TGCT.
Materials and methods
Human subjects and samples
Formalin-fixed paraffin-embedded (FFPE) tissues from 150
cases of testicular germ cell tumors (SE, non-SE, and mixed
tumors) were retrieved from the files of the Department of
Pathology at Barretos Cancer Hospital (Brazil) and Hospital
de Braga (Portugal). All the patients were diagnosed between
2006 and 2012. The samples analyzed were from primary
tumors at diagnosis prior the use of any possible systemic
treatment. All the TGCT cases were reevaluated by a pathol-
ogist to the confirmation of the diagnosis.
Germ cell tumor cell lines
The germ cell tumor cell lines (NTERA-2, 1411H, 1777N and
N2102Ep Clone2/A6) were purchased from the European
Collection of Cell Cultures (ECACC). DNAwas isolated from
cell lines using TRIzol reagent (Life Technologies) following
the manufacturer’s recommendation. Authentication of cell
lines was performed by short tandem repeat (STR) DNA typ-
ing according to the International Reference Standard for
Authentication of Human Cell Lines, as reported by Dirks
et al. [16]. Genotyping confirmed the identity of all cell lines.
DNA isolation from FPPE tissue
DNAwas obtained from FFPE tissue sections representative
of the tumor lesions using the QIAamp® DNA Micro Kit
(Qiagen), following manufacturer’s instructions and as previ-
ously described [17].
TERT mutation and SNP analysis
The analysis of hotspot mutations of TERT promoter regions
was performed by PCR followed by direct Sanger sequencing
as described previously by our group [3, 18, 19].
The electropherogram analysis of the same region allowed
the genotyping of rs2853669 SNP.
Statistical analysis
To assess the relationship between variables, we used the
Fisher’s exact test. The overall survival was assessed by
Kaplan-Meier method, and comparisons between curves were
performed by log-rank test. The p value established for the
statistical significance was <0.05. All the statistical analysis
was performed using SPSS 19.0 software (IBM Corp,
Armonk, NY, USA).
Results
Twelve samples yielded inconclusive results due to DNA
quality issues. Therefore, the major clinical and pathological
features of the 138 patients (70 % from Brazil and 30 % from
Portugal) analyzed with conclusive results are summarized in
Table 1. All IGCCCG [20] risk groups were represented, and
the 5-year overall survival was 84.1 %.
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Table 1 Clinicopathological and molecular features of testicular germ cell tumor (TGCT) and their association with polymorphism
Characteristics Patients TERT promoter mutation SNP rs2853669
N (%) c.-124:C>T c.-146:C>T Percenta All Carrier (C/C+C/T) (TT) Percentb p value
TGCT 138 1 3 2.9 92 34 58 37
Age (mean±SD=30 years±9.5)
<30 years 83 (60.1) 1 2 3.6 52 17 35 32.7 0.33
≥30 years 55 (39.9) 0 1 1.8 40 17 23 42.5
Histology group
Non-seminoma 95 (68.8) 1 2 3.2 62 22 40 35.5 0.67
Seminoma 43 (31.2) 0 1 2.3 30 12 18 40
Histology
Mixed tumor 51 (37.0) 0 1 2 34 15 19 44.1 0.9
Seminoma 43 (31.2) 0 1 2.3 31 12 19 38.7
Embryonal carcinoma 18 (13.0) 1 0 5.6 11 4 7 36.4
Yolk sac tumor 10 (7.2) 0 1 10 6 2 4 33.3
Immature teratoma 7 (5.1) 0 0 0 6 1 5 16.7
Mature teratoma 4 (2.9) 0 0 0 2 0 2 0
Choriocarcinoma 2 (1.4) 0 0 0 1 0 1 0
Missing 3 (2.2) 0 0 0 1 0 1 0
Serum tumor markers (AJCC)
S0 18 (13.0) 0 0 0 17 8 9 47 0.11
S1 32 (23.2) 0 1 3.1 24 4 20 16.7
S2 39 (28.3) 1 1 5.1 22 10 12 45.4
S3 24 (17.4) 0 0 0 16 8 8 50
SX 25 (18.1) 0 1 4 13 4 9 30.8
Staging (AJCC)
I 29 (21.0) 0 2 6.9 24 8 16 33.3 0.6
IS 22 (15.9) 0 0 0 13 7 6 53.8
II 27 (19.6) 0 0 0 18 6 12 33.3
III 60 (43.5) 1 1 3.3 37 13 24 35.1
Number of metastasis site
0 51 (37.0) 0 2 3.9 37 15 22 40.5 0.07
1 36 (26.1) 1 1 5.5 22 11 11 50
2 26 (18.8) 0 0 0 17 2 15 11.8
≥3 10 (7.2) 0 0 0 7 2 5 28.6
Missing 15 (10.9) 0 0 0 9 4 5 44.4
Chemosensitivity
Responsive 94 (68.1) 1 0 1 68 27 41 39.7 0.78
Refractory 20 (14.5) 0 1 5 14 5 9 75.4
No chemotherapy 24 (17.4) 0 2 8.3 10 2 8 20
IGCCCG risk
Good 31 (22.5) 1 0 3.2 22 5 17 22.7 0.22
Intermediate 17 (12.3) 0 1 5.9 12 7 5 58.3
Poor 28 (20.3) 0 0 0 16 6 10 37.5
Not applicable 51 (37.0) 0 2 3.9 37 15 22 40.5
Missing 11 (8.0) 0 0 0 5 1 4 20
AJCC American Joint Committee on Cancer, TERT telomerase reverse transcriptase, IGCCCG International Germ Cell Cancer Cooperative Group
a Percentage of TERT promoter mutation
b Percentage of carriers of the polymorphism
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The mutation screening of the hotspot promoter region of
TERT gene (c.-124:C>T and c.-146:C>T) showed the pres-
ence of the c.-124:C>T in one patient and the c.-146:C>T
TERT mutation in three patients with testicular germ cell tu-
mors (Table 2 and Fig. 1). Three of the four mutated cases
presented primary tumors larger than 6 cm. One of them (case
4, Table 2) was a localized pure seminoma in an older adult,
and the remaining were non-SE tumors in younger patients.
Only one case (case 2, Table 2) corresponded to advanced
refractory disease, and the patient died due to testicular germ
cell tumor. There were no significant associations between
TERT mutation and any of the clinicopathological
characteristics.
SNP rs2853669 genotyping was successful in 66.6 % of
cases, and we found the following genotypes: 8.7 % C/C,
28.2 % T/C, and 63.0 % T/T. The allele frequency for T was
77.2 % and for C was 22.8 %. In the four TERT-mutated
tumors, the SNP genotyping was possible in two and both
exhibited homozygous T (Table 2).
The SNP rs2853669 (C/C+C/T) did not associate with any
clinicopathological characteristic (Table 1). The 5-year overall
survival of C/C+C/T versus TTwas not statistically significant
(respectively 94.1 versus 81.7 %, p=0.33). None of the four
GCT cell lines presented mutations in the hotspot promoter
regions of TERT gene, and concerning the rs2853669, one cell
line (NTERA-2) was C/C and the remaining were T/T.
Discussion
This study reports for the first time the presence of somatic
mutations in the promoter region of TERT gene in TGCT. We
observed a frequency of 2.9 % (4/138) of TERT promoter
mutation. Recent studies have described a high frequency of
TERT promoter mutation in several human tumors and human
cell lines [2–5, 21, 22]. In glioblastomas and papillary thyroid
cancer, the mutations were associated with older age at diag-
nosis [3]. Another recent study demonstrated association



















1 c.-124:C>T Not analyzed 26 Embryonal
carcinoma
6 + S2 III Lymph node Good Responsive Alive
2 c.-146:C>T Not analyzed 22 Yolk sac tumor Unknown − S2 III Lymph node Intermediate Refractory Dead of disease
3 c.-146:C>T TT 19 Mixed tumor 9 − SX I n/a n/a n/a Alive
4 c.-146:C>T TT 43 Seminoma 6.5 + S1 I n/a n/a n/a Alive
n/a not applicable
a Vascular invasion
Fig. 1 Sequencing and histology
of two TGCT cases presenting c.-
146:C>T TERT promoter
mutation. Case 1: a
electropherogram reporting the c.-
146:C>T mutation in a 19-year-
old patient and b H&E staining
demonstrating the mixed TGCT,
containing 50 % of immature
teratoma and 50 % of yolk sac
tumor. Case 2: c
electropherogram reporting the c.-
146:C>T mutation in a 43-year-
old patient and d H&E staining
demonstrating the pure seminoma
tissue. Black arrow indicates the
position of c.-146:C>T mutation
into the TERT promoter region
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between TERT promoter mutations and older patient age, larg-
er tumor size, distant metastases, and shorter disease specific
survival in papillary thyroid cancer [23]. In melanoma, TERT
promoter mutations were also associated with shorter disease
free survival [24]. In our study, we identified TERT promoter
mutations in small number of cases that exhibited different
stages, invasiveness, and histologies, hindering meaningful
statistical associations.
The TERT mutation profile has been associated with other
molecular features in several tumor types, in particular an
interesting association with BRAF mutation in skin melano-
mas and thyroid cancer [3, 4]. The frequency and clinical
impact of BRAF mutations in TGCT is still controversial
[25, 26]. BRAF mutations were not evaluated in the present
study. It is also of note in TGCT that, at variance with the
majority of the other tumor types on record, the c.-146:C>T
mutation was more prevalent than the c.-124:C>T [27].
Further studies are needed to clarify if this observation repre-
sents any biological significance.
In our series, the frequency of allele C (22.8 %) of SNP
rs2853669 in the TERT promoter region was similar to those
found in more than 1000 genome database (30 %) [28]. Two
of our mutated cases could not be analyzed and the other two
showed T/T, the most frequent genotype. Although this poly-
morphism could act as a modifier of the effect of the hotspot
promoter mutations on survival, as seen in bladder cancer and
renal cell carcinoma [8, 9], our study has few mutated cases,
hampering its statistical significance. Nevertheless, in the
whole series, the carriers of the C variant for rs2853669 seem
to have a better outcome. Further studies with larger cohorts
would be needed to test this hypothesis.
Cell immortalization is a cancer hallmark, which is associ-
ated with abnormal telomeres size maintenance [1]. Telomere
size is mainly controlled by telomerase activity, and its abnor-
mal reactivation is reported in up to 90 % of human tumors.
Only recently, Huang et al. [2] and Horn et al. [5] showed that
mutations in the promoter region of TERT gene, namely the c.-
146:C>T and the c.-124:C>T mutations, generate a new con-
sensus binding site for ETS/TCFs transcription factors
(CCGGAA) leading to a two- to fourfold increase of the
TERT promoter activity. The low frequency of TERT promoter
mutations observed in our study raises evidence that other path-
ways may be involved in telomere regulation in TGCT. It is
reported that activation of telomerase can be mediated by Kit
ligand in proliferating spermatogonia and primordial germ
cells, but there is no telomerase activity in sperm cells [29].
Telomerase activity has not been identified in mature terato-
mas, while it is present in other histologies like seminoma,
embryonal carcinoma, mixed tumors, as our third case, and
markedly in immature teratomas [14]. In the TERT-mutated
case, that showed a mixed (immature teratoma and yolk sac
tumor—case 3, Table 2) histology, it was not possible to accu-
rately microdissect both components, hampering to understand
whether the mutation is present in both components or in just
one of them. This finding fits with the mRNA expression of
TERT [30]. Although non-SE germ cell tumors reveal longer
telomeric restriction fragment than seminomas, telomerase ac-
tivity seems to be similar in both groups, and other unknown
factors might play a role [31]. Finally, alternative lengthening
of telomeres (ATL) is a well-known mechanism involved in
non-telomerase-dependent cancer cell immortalization [32],
and its role in TGCT is unexplored.
Our series is very heterogeneous, representative of several
types of germ cell tumor histologies, clinical staging, and re-
sponse to chemotherapy. The predominance of advanced dis-
ease and non-SE histologies in our series differs from the
classical literature, where seminomas and stage I disease is
the most common finding [33]. Our hospital is a reference
center for TGCT, associated to the Brazilian Childhood
Germ Cell Tumor Study Group, a consortium developed to
standardize diagnostic assessment and multidisciplinary treat-
ment of TGCT patients in Brazil [34] and for that reason, our
series might be biased by more advanced cases. However, the
several risk groups were well represented in the study.
Conclusions
TERT promoter mutations seem to be a rare event in TCGTs;
however, we showed for the first time that TERT promoter
mutations can be a new molecular event in a small subset
(2.9 %) of cases. Further studies are needed to extend and
validate these findings, in order to assess the clinical impact
of TERT mutations and rs2853669 polymorphism in TGCT
patients and to associate TERT with the other molecular fea-
tures of TGCT, in particular with BRAF mutation status.
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